文献速递睡眠呼吸障碍

首次终止CPAP后恢复治疗及其对全因死亡率的影响

CPAP resumption after a first termination and impact on all-cause mortality in France.
PubMed 文献 · Eur Respir J · 2024-02-01

该研究基于法国国家医保报销数据,分析103 091例首次终止CPAP治疗的成人OSA患者,26%在12个月内恢复CPAP,其中65%持续使用1年。匹配分析显示,恢复后持续使用CPAP者全因死亡风险较再次终止者低38%(HR 0.62,95%CI 0.48-0.79;p=0.0001)。

要点

  • 首次终止CPAP后26%患者恢复治疗,其中65%持续使用1年。
  • 恢复后持续使用CPAP与全因死亡风险降低38%相关(HR 0.62)。
  • 男性、高血压及呼吸科医生处方是恢复后持续使用的预测因素。

核心结论

  • OSA患者首次CPAP治疗失败后恢复并持续使用CPAP与全因死亡风险降低相关,提示应提供第二次试用机会。

研究设计与样本

  • 基于法国国家医保报销系统的回顾性队列分析,纳入103 091例首次终止CPAP治疗的成人OSA患者。

主要发现

  • 首次终止后12个月内26%恢复CPAP,其中65%在1年后仍使用。
  • 恢复后持续使用CPAP者较第二次终止者全因死亡风险低38%(HR 0.62,95%CI 0.48-0.79;p=0.0001)。
  • 男性、高血压和呼吸科医生处方是恢复后持续使用CPAP的显著预测因素。

关键数值与推荐

  • 全因死亡风险降低38%(HR 0.62,95%CI 0.48-0.79;p=0.0001),比较恢复后持续使用CPAP者与第二次终止者。

临床怎么用

  • 对首次CPAP治疗失败的OSA患者,应考虑提供第二次试用,避免有效治疗被遗漏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuation of continuous positive airway pressure (CPAP) therapy after initial prescription has been shown to reduce all-cause mortality versus therapy termination. However, there is a lack of data on the rates and impact of resuming CPAP in patients with obstructive sleep apnoea (OSA). This analysis determined the prevalence of CPAP resumption in the year after termination, characterised determinants of CPAP resumption, and examined the impact of CPAP resumption on all-cause mortality. METHODS: French national health insurance reimbursement system data for adults aged ≥18 years were used. CPAP prescription was identified by specific treatment codes. Patients who resumed CPAP after first therapy termination and continued to use CPAP for 1 year were matched with those who resumed CPAP then terminated therapy for a second time. RESULTS: Out of 103 091 individuals with a first CPAP termination, 26% resumed CPAP over the next 12 months, and 65% of these were still using CPAP 1 year later. Significant predictors of CPAP continuation after resumption included male sex, hypertension and CPAP prescription by a pulmonologist. In the matched population, the risk of all-cause death was 38% lower in individuals who continued using CPAP after therapy resumption versus those who had a second therapy discontinuation (hazard ratio 0.62, 95% CI 0.48-0.79; p=0.0001). CONCLUSION: These data suggest that individuals with OSA who fail initial therapy with CPAP should be offered a second trial with the device to ensure that effective therapy is not withheld from those who might benefit.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Pépin JL, Tamisier R, Benjafield AV, et al. CPAP resumption after a first termination and impact on all-cause mortality in France. Eur Respir J. 2024. PMID: 38135441. doi:10.1183/13993003.01171-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。